XBiotech Inc. (XBIT) · Oct 26, 2026 · Exec change
Co-CEO agreement — $150,000 base salary; 2,000,000 options vesting over three years
XBiotech’s executive change is now formal: Jan-Paul Simard gets a $150,000 base salary and 2 million stock options as Co-CEO.
XBiotech is a development-stage biotechnology company advancing its True Human antibody pipeline, including oncology and inflammatory-disease programs, with recent Phase II activity in colorectal cancer and axial spondyloarthritis. This filing formalizes a leadership change that was already public. The company had announced on October 23, 2026 that Jan-Paul Simard would serve as Co-CEO alongside Sushma Shivaswamy, so the appointment itself is not a fresh surprise. The new agreement makes the arrangement contractual and assigns Simard strategic and operational responsibilities alongside Shivaswamy. 〔0〕 The new information is the compensation and incentive structure. Simard receives a $150,000 annual base salary, prorated for 2026, plus 2,000,000 options priced at the October 26 closing share price. 〔1〕 〔2〕 The option grant creates a real but unquantified dilution overhang. The options vest in six equal installments over three years, aligning Simard with execution of the clinical pipeline but potentially increasing future share dilution; the filing does not state the grant as a percentage of shares outstanding. Bottom line: This is mainly the contractual completion of a leadership transition already disclosed, not a new strategic pivot. It adds execution incentives but also a sizeable option grant, leaving the business impact dependent on whether the shared leadership structure advances XBiotech’s clinical programs.**
Clinical execution under the new co-CEO structure
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!